Evidence map›Paper›PMID 35887169›Full record

ArticleInternational journal of molecular sciences2022

Unkeito Suppresses RANKL-Mediated Osteoclastogenesis via the Blimp1-Bcl6 and NF-κB Signaling Pathways and Enhancing Osteoclast Apoptosis.

Ke Fang, Yuki Murakami, Seiji Kanda, Takaki Shimono, Anh Tuan Dang, Mitsuaki Ono, Toshimasa Nishiyama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ke FangDepartment of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.ORCID 0000-0002-7390-8488
Yuki MurakamiDepartment of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.ORCID 0000-0002-7085-4832
Seiji KandaDepartment of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.ORCID 0000-0002-1797-3509
Takaki ShimonoDepartment of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.
Anh Tuan DangDepartment of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Mitsuaki OnoDepartment of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Toshimasa NishiyamaDepartment of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.
Kansai Medical University · JPOkayama University · JP

Funding

Promotion and Mutual Aid Corporation for Private Schools of Japan No number
6 · The paper itself

Abstract

Osteoporosis is a common bone disease, particularly in menopausal women. Herein, we screened four Kampo medicines (Unkeito (UKT), Kamishoyosan (KSS), Kamikihito (KKT), and Ninjinyoeito (NYT)), frequently used to treat menopausal syndromes, for their effects on receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation in RAW 264 cells. Considering that UKT exhibited the most potent effect, we examined its effect on RANKL-induced osteoclastogenesis, the induction of osteoclast apoptosis, and the mechanisms underlying its effects. UKT inhibits RANKL-induced osteoclast differentiation in the early stage and decreases osteoclast-related genes, including tartrate-resistant acid phosphatase (

Indexed as

Bone ResorptionOsteoclastsAnimalsApoptosisCell DifferentiationFemaleHumansMiceNFATC Transcription FactorsNF-kappa BOsteogenesisPositive Regulatory Domain I-Binding Factor 1Proto-Oncogene Proteins c-bcl-6RANK LigandSignal TransductionBCL6 protein, humanBcl6 protein, mouseNFATC Transcription FactorsNF-kappa BPositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseProto-Oncogene Proteins c-bcl-6RANK Ligandcaspase-3NFATc1osteoporosisp65postmenopauseUnkeito

Identifiers

PMID35887169
PMCPMC9323376
OpenAlexW4285733378

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.